GlassScriptPhysician profile
Mark Elliot Wagner
NPI 1033202502
$6,742.04
in general payments reported to CMS, 2019-2025
47 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $664 · 2021: $726 · 2022: $921 · 2023: $1,114 · 2024: $924 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403 · Education: $52.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,402.86 |
| Education | $52.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,088.38 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $740.06 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $637.73 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $403.76 | 2019-2025 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.06 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Novartis Pharmaceuticals Corporation | $378.60 | 2019-2025 | |
| Lilly USA, LLC | $377.40 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Teva Pharmaceuticals USA, INC. | $320.06 | 2019-2022 | |
| Astellas Pharma US INC | $307.78 | 2019-2025 | Veozah |
| Pfizer INC. | $298.17 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $272.39 | 2020-2025 | Rexulti |
| Abbott Laboratories | $143.15 | 2022-2023 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $137.88 | 2024 | Voquezna |
| Amarin Pharma, INC. | $120.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $120.05 | 2019-2023 | Belsomra |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.